Cas9 Cuts and Consequences; Detecting, Predicting, and Mitigating CRISPR/Cas9 On- and Off-Target Damage: Techniques for Detecting, Predicting, and Mitigating the On- and off-target Effects of Cas9 Editing
| dc.contributor.author | Newman, Anthony | |
| dc.contributor.author | Starrs, Lora | |
| dc.contributor.author | Burgio, Gaetan | |
| dc.date.accessioned | 2022-10-04T00:51:18Z | |
| dc.date.available | 2022-10-04T00:51:18Z | |
| dc.date.issued | 2020-07-09 | |
| dc.date.updated | 2021-11-28T07:20:55Z | |
| dc.description.abstract | Large deletions and genomic re-arrangements are increasingly recognized as common products of double-strand break repair at Clustered Regularly Interspaced, Short Palindromic Repeats - CRISPR associated protein 9 (CRISPR/Cas9) on-target sites. Together with well-known off-target editing products from Cas9 target misrecognition, these are important limitations, that need to be addressed. Rigorous assessment of Cas9-editing is necessary to ensure validity of observed phenotypes in Cas9-edited cell-lines and model organisms. Here the mechanisms of Cas9 specificity, and strategies to assess and mitigate unwanted effects of Cas9 editing are reviewed; covering guide-RNA design, RNA modifications, Cas9 modifications, control of Cas9 activity; computational prediction for off-targets, and experimental methods for detecting Cas9 cleavage. Although recognition of the prevalence of on- and off-target effects of Cas9 editing has increased in recent years, broader uptake across the gene editing community will be important in determining the specificity of Cas9 across diverse applications and organisms. | en_AU |
| dc.description.sponsorship | This work was partly supported from the National Health and Medical Research Council of Australia (APP1143008), the Australian Research Council (DP180101494), the National Natural Science Foundation of China (81772214), The Australian Rese the National Collaborative Research Infrastructure Strategy (NCRIS) via, Phenomics Australian. A.N. is supported from an Australian Government Research Training Program Scholarship. | en_AU |
| dc.format.mimetype | application/pdf | en_AU |
| dc.identifier.issn | 0265-9247 | en_AU |
| dc.identifier.uri | http://hdl.handle.net/1885/274254 | |
| dc.language.iso | en_AU | en_AU |
| dc.provenance | https://v2.sherpa.ac.uk/id/publication/14547..."Author Accepted Manuscript can be made open access on non-commercial institutional repository after 12 month embargo" from SHERPA/RoMEO site (as at 4.10.2022). | en_AU |
| dc.publisher | The Company of Biologists Ltd | en_AU |
| dc.relation | http://purl.org/au-research/grants/nhmrc/1143008 | en_AU |
| dc.relation | http://purl.org/au-research/grants/arc/DP180101494 | en_AU |
| dc.rights | © 2020 WILEY Periodicals, Inc. | en_AU |
| dc.source | Bioessays | en_AU |
| dc.subject | CRISPR/Cas9 | en_AU |
| dc.subject | double-stranded breaks | en_AU |
| dc.subject | guide RNA design | en_AU |
| dc.subject | highthroughput sequencing | en_AU |
| dc.subject | machine learning | en_AU |
| dc.subject | off-target effects | en_AU |
| dc.subject | on-target effects | en_AU |
| dc.title | Cas9 Cuts and Consequences; Detecting, Predicting, and Mitigating CRISPR/Cas9 On- and Off-Target Damage: Techniques for Detecting, Predicting, and Mitigating the On- and off-target Effects of Cas9 Editing | en_AU |
| dc.type | Journal article | en_AU |
| dcterms.accessRights | Open Access | en_AU |
| local.bibliographicCitation.issue | 9 | en_AU |
| local.bibliographicCitation.lastpage | 13 | en_AU |
| local.bibliographicCitation.startpage | 1 | en_AU |
| local.contributor.affiliation | Newman, Anthony, College of Health and Medicine, ANU | en_AU |
| local.contributor.affiliation | Starrs, Lora, College of Health and Medicine, ANU | en_AU |
| local.contributor.affiliation | Burgio, Gaetan, College of Health and Medicine, ANU | en_AU |
| local.contributor.authoruid | Newman, Anthony, u5567363 | en_AU |
| local.contributor.authoruid | Starrs, Lora, u4301798 | en_AU |
| local.contributor.authoruid | Burgio, Gaetan, u5727247 | en_AU |
| local.description.notes | Imported from ARIES | en_AU |
| local.identifier.absfor | 320601 - Gene and molecular therapy | en_AU |
| local.identifier.absfor | 320603 - Medical molecular engineering of nucleic acids and proteins | en_AU |
| local.identifier.absfor | 310113 - Synthetic biology | en_AU |
| local.identifier.absseo | 240803 - Human pharmaceutical treatments | en_AU |
| local.identifier.absseo | 280103 - Expanding knowledge in the biomedical and clinical sciences | en_AU |
| local.identifier.absseo | 200105 - Treatment of human diseases and conditions | en_AU |
| local.identifier.ariespublication | a383154xPUB14580 | en_AU |
| local.identifier.citationvolume | 42 | en_AU |
| local.identifier.doi | 10.1002/bies.202000047 | en_AU |
| local.identifier.scopusID | 2-s2.0-85087728530 | |
| local.publisher.url | https://onlinelibrary.wiley.com/ | en_AU |
| local.type.status | Accepted Version | en_AU |
Downloads
Original bundle
1 - 1 of 1
Loading...
- Name:
- bies.202000047.pdf
- Size:
- 1.33 MB
- Format:
- Adobe Portable Document Format
- Description: